SOANinactive

GLOBESTAR THERAPEUTICS CORP

Healthcare·Neurology·Pre-clinical
NeurologyImmunology

GLOBESTAR THERAPEUTICS CORP (SOAN): 4 pipeline candidates · ~4 mo cash runway. Updated within the last hour.

5.1/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.0

3.7 months

Financial Health10.0

D/E -1.05 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for GLOBESTAR THERAPEUTICS CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$41

Quarterly Burn

$20K

Runway

3.7 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2026
Today~7 mo out
Catalyst within runway

Pipeline (4 candidates)

DrugPhase
ms treatmentPreclinical
patented formulation of previously approved drugsPreclinical
project amethystPreclinical
u.s. patent 10—

Frequently asked questions

How many drug candidates are in GLOBESTAR THERAPEUTICS CORP's pipeline?

GLOBESTAR THERAPEUTICS CORP (SOAN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is GLOBESTAR THERAPEUTICS CORP's lead drug candidate?

GLOBESTAR THERAPEUTICS CORP's most advanced tracked candidate is ms treatment (Preclinical) for Multiple Sclerosis.

What is GLOBESTAR THERAPEUTICS CORP's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, GLOBESTAR THERAPEUTICS CORP has approximately 3.7 months of cash runway.

Get the full picture on GLOBESTAR THERAPEUTICS CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar